- Home
- APLS vs EWTX Comparison
APLS vs EWTX Comparison
Compare APLS & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLS | EWTX |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | APLS | EWTX |
|---|---|---|
| Price | $24.97 | $26.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 8 |
| Target Price | $33.89 | ★ $34.13 |
| AVG Volume (30 Days) | ★ 2.3M | 1.8M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,016,397,000.00 | N/A |
| Revenue This Year | $28.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $69.72 | ★ N/A |
| Revenue Growth | ★ 42.11 | N/A |
| 52 Week Low | $16.10 | $10.60 |
| 52 Week High | $35.57 | $30.48 |
Technical Indicators
Market Signals| Indicator | APLS | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 59.39 |
| Support Level | $24.25 | $19.76 |
| Resistance Level | $26.12 | $27.40 |
| Average True Range (ATR) | 1.03 | 2.27 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 51.94 | 85.80 |
Price Performance
Historical ComparisonAbout APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.